Trinity Health Names Mark LePage, M.D., as Senior Vice President of Medical Groups and Ambulatory Strategy

Trinity Health today announced it has named Mark LePage, M.D., M.B.A., as the new senior vice president, medical groups and ambulatory strategy, effective July 1, 2021. In this position, LePage will take on national responsibility for Trinity Health’s medical groups, leading more than 6,800 physicians and clinicians.

LePage comes to the position after spending four years as the first physician CEO of IHA, Trinity Health’s largest multi-specialty medical group. He is a board-certified vascular and interventional radiologist with a background that spans clinical experience, financial acumen and strategic planning. Under his leadership, IHA successfully expanded into the broader Detroit metro area, acquired a 21-provider primary care group, assumed management oversight over St. Joe’s Medical Group, and worked together with an independent physician organization to develop a Medicare Shared Savings Program.

“We look forward to the leadership Mark will bring as Trinity Health continues to advance our medical groups and ambulatory strategy to deliver an exceptional member experience and excellent clinical, operational, and financial outcomes,” said Trinity Health chief clinical officer Dan Roth, M.D.

Prior to his time at IHA, LePage served as chief medical officer of Marshfield Clinic in Wisconsin, where he led clinical operations of the 700-physician multispecialty medical group. Before his time with Marshfield, he served in the United States Air Force as a Staff Interventional Radiologist at Lackland Air Force Base in Texas.

LePage holds a Bachelor of Science from the University of Michigan and received his medical degree with distinction from the University of Michigan Medical School. He also holds a Master of Business Administration and a Master of Finance from the Kelley School of Business at Indiana University, and completed a Value Measurement for Health Care course at Harvard Business School.

He currently serves on the American Medical Group Association Public Policy Committee, the Board of Trustees for St. Mary Mercy Livonia Hospital, the Ann Arbor SPARK Board of Directors, and the Ann Arbor-Ypsilanti Regional Chamber Board of Directors.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version